ArticleInvestigational new drugs2023

A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors.

Victor Moreno et al.PubMed ↗Publisher ↗

No numbers read from the abstract.